Cyclerion Therapeutics, Inc.
CYCN
$2.76
$0.2158.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 93.00K | 81.00K | 1.81M | 194.00K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 93.00K | 81.00K | 1.81M | 194.00K | -- |
| Cost of Revenue | 56.00K | -- | -- | -- | 105.00K |
| Gross Profit | 37.00K | 81.00K | 1.81M | 194.00K | -105.00K |
| SG&A Expenses | 1.71M | 1.50M | 1.25M | 1.24M | 1.28M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.77M | 1.54M | 1.30M | 1.32M | 1.38M |
| Operating Income | -1.67M | -1.46M | 502.00K | -1.13M | -1.38M |
| Income Before Tax | -324.00K | -1.43M | 530.00K | -723.00K | -1.32M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -324.00K | -1.43M | 530.00K | -723.00K | -1.32M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -324.00K | -1.43M | 530.00K | -723.00K | -1.32M |
| EBIT | -1.67M | -1.46M | 502.00K | -1.13M | -1.38M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.11 | -0.56 | 0.21 | -0.29 | -0.53 |
| Normalized Basic EPS | -0.33 | -0.35 | 0.13 | -0.18 | -0.33 |
| EPS Diluted | -0.11 | -0.56 | 0.21 | -0.29 | -0.53 |
| Normalized Diluted EPS | -0.33 | -0.35 | 0.13 | -0.18 | -0.33 |
| Average Basic Shares Outstanding | 3.07M | 2.56M | 2.54M | 2.53M | 2.51M |
| Average Diluted Shares Outstanding | 3.07M | 2.56M | 2.54M | 2.53M | 2.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |